Dr.Mitchell Ho is a Senior Investigator and Chief of the Antibody Therapy Sectionat the National Cancer Institute (NCI), NIH. He is also the Chair of theDepartment of Biochemistry for the FAES Graduate School at the NIH. He receiveda B.S. in Biology from East China Normal University and a M.A. in Cell andMolecular Biology from San Francisco State University. He became interested inphage display antibody engineering during his work at Protein Design Labs. Heobtained a Ph.D. in Immunology from the University of Illinois atUrbana-Champaign where he received a NIDA/NRSA fellowship with Mariangela Segreto design anti-idiotypic antibodies as cocaine antagonists. He was apostdoctoral fellow with Ira Pastan at the NCI where Dr. Ho was involved in thedevelopment of recombinant immunotoxins targeting CD22 and mesothelin that arecurrently being tested in clinical trials including Phase III for cancertreatment. Dr. Ho serves on the Board of Distinguished Advisors for theAntibody Society.